The National Medical Products Administration has conditionally approved the marketing of Trizinutide tablets.

Recently, the National Medical Products Administration approved the market launch of the class 1 innovative drug Tenegetin Tablets, submitted by Jiangsu Aosaikang Pharmaceutical Co., Ltd., through a priority review and approval process. This drug is used for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received systemic therapy and FGFR inhibitor therapy, and possess fibroblast growth factor receptor 2 fusion or rearrangement. The market launch of this drug provides patients with new treatment options.